Combination of the PARP inhibitor olaparib with the vascular disrupting agent NOV202 reduces tumor growth in BRCA1/2 mutated prostate cancer xenografts by Bjartell, A.S, Sereti, E, Evans Axelsson, S

Get full text

PIONEER - prioritisation of the most important questions in the field of prostate cancer by Omar, M.I, Dimitropolous, K, Gandaglia, G, Fossati, N, Van Den Broeck, T, Evans-Axelsson, S, Van Den Bergh, R, Maclennan, S, Bjartell, A, N’dow, J

Get full text

PIONEER: European Commission Innovative Medicines Initiative funded BD4BO (Big data for better outcome) project on prostate cancer by Evans Axelsson, S, Abbott, T, Fullwood, L, Omar, M.I, Cavelaars, M, Asiimwe, A, Roobol, M, Ribal, M.J, Auffray, C, Devecseri, Z, Smith, E.J, Van Hemelrijck, M, MacLennan, S, Horgan, D, Reich, C, De Meulder, B, Lancet, D, Bangma, C, Briganti, A, Tilki, D, Van Poppel, H, Wirth, M.P, N’Dow, J, Bjartell, A

Get full text

Combination of the PARP inhibitor olaparib with a novel vascular disrupting agent, NOV202, reduces tumor growth in BRCA1/2 mutated prostate cancer xenografts by Sereti, E, Evans-Axelsson, S, Hellsten, R, Rehnmark, S, Högberg, M, Bjartell, A

Get full text

P135 Big data analysis of adverse events in metastatic hormone-sensitive prostate cancer systemic treatment using the PIONEER platform by Rajwa, P, Borkowetz, A, Abbott, T, Alberti, A, Bjartell, A, Brash, J, Chilelli, A, Davies, E, De Meulder, B, Golozar, A, Hijazy, A, Josefsson, A, Kolde, R, Kotik, D, Nicoletti, R, Oja, M, Prinsen, P, Ribal, M, Gómez Rivas, J, Smith, E, Snijder, R, Steinbeisser, C, Gandaglia, G, Cornford, P, Evans-Axelsson, S, N'dow, J, Peter-Paul, W

Get full text

Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer by Witt, Kristina, Evans-Axelsson, Susan, Lundqvist, Andreas, Johansson, Martin, Bjartell, Anders, Hellsten, Rebecka

Get full text

20 - Combination of the PARP inhibitor olaparib with the vascular disrupting agent NOV202 reduces tumor growth in BRCA1/2 mutated prostate cancer xenografts by Bjartell, A.S., Sereti, E., Evans Axelsson, S.

Get full text

A novel vascular disrupting agent (NOV202) increases the anticancer efficacy of the PARP inhibitor olaparib in prostate cancer cells with BRCA1/2 mutations by Sereti, E., Evans-Axelsson, S., Rehnmark, S., Högberg, M., Bjartell, A.

Get full text

A comprehensive overview of patient reported outcomes: Results from the PIONEER consortium by Remmers, S., Beyer, K., Prinsen, P., Barletta, F., Brunckhorst, O., Gandaglia, G., Smith, E.J., Collette, L., Evans-Axelsson, S., N’Dow, J., Roobol, M.J., Van Hemelrijck, M., Venderbos, L.D.F.

Get full text

A0496 - A comprehensive overview of patient reported outcomes: Results from the PIONEER consortium by Remmers, S., Beyer, K., Prinsen, P., Barletta, F., Brunckhorst, O., Gandaglia, G., Smith, E.J., Collette, L., Evans-Axelsson, S., N’Dow, J., Roobol, M.J., Van Hemelrijck, M., Venderbos, L.D.F.

Get full text

AGREE II quality assessment of national and international clinical practice guidelines on prostate cancer by Beyer, K., Bhattacharya, Y., Murray, C., Smith, E.J., Boissier, R., Borkowetz, A., Dabestani, S., Willemse, P-P.M., Maresca, G., Rivas, J.G.M., Rajwa, P., Lardas, M., Grivas, N., Sakalis, V., Evans-Axelsson, S., Maclennan, S., Auweter, S., Thomas, M., Bjartell, A., Cornford, P., Kruger, H., N’dow, J., Roobol, M., Omar, M.I.

Get full text

A0859 - AGREE II quality assessment of national and international clinical practice guidelines on prostate cancer by Beyer, K., Bhattacharya, Y., Murray, C., Smith, E.J., Boissier, R., Borkowetz, A., Dabestani, S., Willemse, P-P.M., Maresca, G., Rivas, J.G.M., Rajwa, P., Lardas, M., Grivas, N., Sakalis, V., Evans-Axelsson, S., Maclennan, S., Auweter, S., Thomas, M., Bjartell, A., Cornford, P., Kruger, H., N’dow, J., Roobol, M., Omar, M.I.

Get full text

UP19 - Combination of the PARP inhibitor olaparib with a novel vascular disrupting agent, NOV202, reduces tumor growth in BRCA1/2 mutated prostate cancer xenografts by Sereti, E., Evans-Axelsson, S., Hellsten, R., Rehnmark, S., Högberg, M., Bjartell, A.

Get full text

The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer by Beyer, Katharina, MacLennan, Sara J., Moris, Lisa, Mastris, Ken, Hooker, Gary, Greene, Robert, Healey, Jemma, Tripathee, Sheela, Venderbos, Lionne D.F., Smith, Emma J., Bjorkqvist, Josefine, Huber, Johannes, Roobol, Monique J., Zong, Jihong, Bjartell, Anders, MacLennan, Steven, Van Hemelrijck, Mieke, Plass, Karin, Shepherd, Robert, Lardas, Michael, Gacci, Mauro, Bjartell, Anders, Evans-Axelsson, LU Susan, Briganti, Alberto, Crosti, Daniele, Garzonio, Roberto, Bangma, Chris, Tilki, Derya, Auvinen, Anssi, Visakorpi, Tapio, Talala, Kirsi, Tammela, Teuvo, Siltari, Aino, Van Hemelrijck, Mieke, Lejeune, Stephane, van Diggelen, Femke, Byrne, Sophie, Fialho, Luz, Cardone, Antonella, Gono, Paulina, De Meulder, Bertrand, Balaur, Irina-Afrodita, Power, Shaun, Kermani, Nazanin Zounemat, van Bochove, Kees, Cirillo, Elisa, Moinat, Maxim, Voss, Emma, Horgan, Denis, Holtorf, Marc, MacLennan, Sara, Wirth, Manfred, Brenner, Beate, Horn, Friedemann, Tandefelt, Delila Gasi, Hugosson, Jonas, Schalken, Jack, Hofmarcher, Thomas, Lindgren, Peter, Andersson, Emelie, Asiimwe, Alex, Zong, Jihong, Butler-Ransohoff, John-Edward, Williamson, Todd, Chandrawansa, Kumari, Waldeck, Reg, Molnar, Megan, Bruno, Amanda, Herrera, Ronald, Nevedomskaya, Ekaterina, Fatoba, Samuel, Constantinovici, Niculae, Mohamed, Ateesha, Steinbeißer, Carl, Maass, Monika, Torremante, Patrizia, Voss, Marc Dietrich, Devecseri, Zsuzsanna, Abbott, Tom, Kiran, Amit, Papineni, Kishore, Wang-silvanto, Jing, Snijder, Robert, Lambrecht, Mark, Wolfinger, Russ, Rogiers, Stijn, Servan, Angela, Samir, Mohamed, Pascoe, Katie, Robinson, Paul, Reich, Christian, Ratwani, Shilpa, Longden-Chapman, Elaine, Burke, Danny, Agapow, Paul, Licour, Muriel, Payne, Sarah, Thompson, Lucy, Bussmann, Michael, Juckeland, Guido

Get full text

725 Intratumoral distribution and pharmacokinetics of the radiolabeled ICAM-1 targeting monoclonal antibody, R6.5 in a prostate cancer mouse model by Evans, Axelsson S, Örbom, A, Jansson, B, Vilhelmsson, Timmermand O, Tran, T.A, Bjartell, A, Strand, S-E

Get full text

How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis by Siltari, Aino, Pang, Karl, Shiranov, Kirill, Asiimwe, Alex, Evans-Axelsson, Susan, Franks, Billy, Kiran, Amit, Murtola, Teemu J., Schalken, Jack, Auvinen, Anssi, N’Dow, J., Smith, E.J., Ribal, M., Mottet, N., Moris, L., Lardas, M., Willemse, P-P., Gandaglia, G., Campi, R., Nicoletti, Rossella, Gacci, M., Briganti, A., Ratti, M.M., Alleva, E., Leardini, L., Sisca, E.S., Bangma, R., Roobol, M., Remmers, S., Tilki, D., Visakorpi, T., Tammela, T., van Hemelrijck, M., Bayer, K., Lejeune, S., Byrne, S., Fialho, L., Auffray, C., Hijazy, A., Power, S., van Bochove, K., Kalafati, M., Moinat, M., Voss, E., Horgan, D., Fullwood, L., Lancet, D., Bernstein, G., Omar, I., MacLennan, S., Maclennan, S., Tripathee, S., Wirth, M., Brenner, B., Borkowetz, A., Thomas, C., Horn, F., Reiche, K., Kreux, M., Josefsson, A., Hugosson, J., Huisman, H., Schalken, J., Hofmacher, T., Lindgren, P., Andersson, E., Zong, J., Butler-Ransohoff, J-E., Maass, M., Torremante, P., Voss, M.D., Devecseri, Z., Dau, C., Papineni, K., Snijder, R., Lambrecht, M., Wolfinger, R., Rogiers, S., Servan, A., Antoni, L., Pacoe, K., Robinson, P., Bakkard, D., Turunen, H., Kilkku, O., Voima, O., Nevalaita, L., Reich, C., Araujo, S., Longden-Chapman, E., Burke, D., Agapow, P., Derkits, S., Licour, M., McCrea, C., Payne, S., Yong, A., Thompson, L., Bussmann, M, Kotik, D.

Get full text

An optimised Bcl-3 inhibitor for melanoma treatment by Saamarthy, Karunakar, Daams, Renée, Sime, Wondossen, Persson, Cecilia, Chygorin, Eduard, Ahlqvist, Kristofer, Evans-Axelsson, Susan, Strand, Daniel, Massoumi, Ramin

Get full text

Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model by Canesin, Giacomo, Evans-Axelsson, Susan, Hellsten, Rebecka, Krzyzanowska, Agnieszka, Prasad, Chandra P, Bjartell, Anders, Andersson, Tommy

Get full text

The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer by Canesin, Giacomo, Evans-Axelsson, Susan, Hellsten, Rebecka, Sterner, Olov, Krzyzanowska, Agnieszka, Andersson, Tommy, Bjartell, Anders

Get full text

Radioimmunotherapy for Prostate Cancer — Current Status and Future Possibilities by Evans-Axelsson, Susan, PhD, Timmermand, Oskar Vilhelmsson, PhD, Bjartell, Anders, MD, PhD, Strand, Sven-Erik, PhD, Elgqvist, Jörgen, PhD

Get full text